Latest Options News

Havilah Resources has secured a binding term sheet with Sandfire Resources for a potential $210 million earn-in at Kalkaroo, while reporting high-grade uranium results and raising $2 million in a share placement.

Redivium Limited is advancing a recapitalisation strategy with Australian investors to meet ASX requirements and resume trading after a prolonged suspension.

Atlantic Lithium has secured £3 million through two share placements with Long State Investments, issuing new warrants and security shares to strengthen its financial footing ahead of Ghana's first lithium mine development.

Sports Entertainment Group Limited (SEG) reports a robust start to FY26 with a 63% jump in underlying EBITDA and advances its strategic exit from Perth Wildcats.

Anatara Lifesciences has completed the final tranche of its placement, issuing over 66 million shares and granting options to its lead manager, marking a key step in its capital raising strategy.

InhaleRX Limited has announced a non-renounceable entitlement offer to raise approximately $247,668 by issuing nearly 10 million new shares at 2.5 cents each, accompanied by free attaching options. The offer opens on 5 December and closes on 17 December 2025.

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

Alma Metals Limited has announced a Share Purchase Plan offering eligible Australian and New Zealand shareholders the chance to buy new shares at a 15% discount, aiming to bolster its capital base ahead of year-end.

Impact Minerals Limited’s recent attempt to issue options to placement participants was rejected by shareholders at the AGM, halting a key incentive plan while the company continues to focus on its high-purity alumina projects.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Harvey Norman Holdings detailed its expansive international growth and omni-channel strategy at its 2025 AGM, highlighting new flagship stores and AI-driven retail innovations across eight countries.

Sarytogan Graphite Limited has raised $1.8 million through a placement to fund its Definitive Feasibility Study and advance key project development activities at its strategic graphite deposit in Kazakhstan.